The FDA has granted a Breakthrough Therapy designation to the antibody-drug conjugate enfortumab vedotin for patients with locally advanced or metastatic urothelial cancer.
Original Article: Enfortumab Vedotin Granted Breakthrough Designation for Metastatic Bladder Cancer